Hit Identification to 3 Compounds in the Clinic and 6 Development Candidates
- UK-based small molecule drug discovery company
- Focus on identifying novel treatments of inflammatory respiratory diseases, such as COPD
- No in-house medicinal chemistry capability – Sygnature has been the company’s exclusive
medicinal chemistry team since 2007, providing multiple FTEs of resource + intellectual input - Considerable intellectual input from Sygnature’s chemists – named on more than 20 patents and patent applications (so far)
- 3 Compounds discovered at Sygnature have entered the clinic (Phases I and IIa) as potential ‘first-in-class’ treatments, and 6 more compounds have entered pre-clinical development
- The company was acquired by a major multi-national pharmaceutical company in 2010
- Since the acquisition, Sygnature has enjoyed a large FTE-based collaboration (medicinal
chemistry and in vitro bioscience) to discover additional small molecule-based drug candidates